ALC = absolute lymphocyte count; CI = confidence interval; CLL = chronic lymphocytic leukemia; IgV H = immunoglobulin heavy chain; MFI = mean fluorescence intensity; TTT = time from diagnosis to initial treatment W ith the widespread use of automated blood cell counters and flow cytometric immunophenotyping, 60% to 80% of patients with chronic lymphocytic leukemia (CLL) now have their condition diagnosed at an early stage of disease. 1 Approximately half of patients with early-stage disease have accelerated disease progression, whereas many of the remaining patients can survive for more than a decade without requiring therapy. 2 The immunoglobulin heavy chain (IgV H ) gene mutation status, leukemic cell expression of CD38 and 70-kD ζ-associated protein, and chromosome analysis by fluorescence in situ hybridization have all been useful in identifying patients with early-stage disease with biologically aggressive disease and shorter survival times. [3] [4] [5] [6] [7] Unfortunately, all these new prognostic tests are expensive and require considerable technical expertise and equipment and thus are not available to many patients with CLL, especially those with limited resources or living in developing countries. Therefore, alternative, less expensive predictive tests are needed.
Smudge cells are CLL cells ruptured during smear preparation. The interpatient variability in the percentage of smudge cells on a peripheral blood smear has long been recognized and is independent of the absolute lymphocyte count (ALC) and method of staining. 8 Using a proteomic approach, we recently discovered that expression of the cytoskeletal protein vimentin is higher in leukemic cells from patients with CLL and unmutated CLL than in those with mutated IgV H genes. 9 High vimentin expression is associated with progressive disease and a shortened time from diagnosis to initial treatment (TTT). Because vimentin increases lymphocyte rigidity, 10 we hypothesized that leukemic cells with an increased vimentin content would be less likely to rupture. Thus, patients with CLL with increased vimentin expression would have a lower percentage of smudge cells on their peripheral blood smears compared with patients with low vimentin expression. Because decreased vimentin expression correlates with both mutated IgV H gene mutation status and favorable prognosis, we hypothesized that a higher percentage of smudge cells on routine peripheral blood smears would predict a better prognosis for patients with early-stage CLL. 
PATIENTS AND METHODS

PERIPHERAL BLOOD SMEAR EXAMINATION
Archived Wright-Giemsa-stained blood smears originally obtained for clinical purposes were reviewed. The smear obtained closest to the date of diagnosis was used for each patient. In 15 patients, a second archived specimen was also evaluated to determine the variability of the percentage of smudge cells over time. The blood smears were prepared from either EDTA anticoagulated blood or a finger stick. All blood smears were prepared using a semiautomatic device used by our laboratory since the 1980s (Miniprep; Sedona Lab Products, Sedona, Ariz) in which a simple spring mechanism pulls a drop of blood along a slide. According to established criteria, smudge cells were defined as broken cells with no intact cytoplasm and a disrupted nuclear membrane (Figure 1) . 12 A total of 200 lymphocytes and smudge cells were counted on each slide and the results expressed as a percentage of the total lymphocytes (intact and smudged).
Because some other laboratories use the manual wedge method, in which a drop of blood is manually pulled by a glass cover, or the Autoprep (Sedona Lab Products) semiautomatic method (essentially the same procedure as the Miniprep), we also freshly prepared peripheral blood smears from 10 patients with CLL using each of these methods to allow comparison of smudging using these different techniques. In addition, to determine the reproducibility and consistency of smear smudge cell counts among different observers, peripheral smears were made and read in a blinded manner by 3 hematopathology technologists.
VIMENTIN EXPRESSION BY CLL CELLS
Vimentin expression in peripheral blood CLL cells was measured by flow cytometry. Briefly, mononuclear cells isolated by density gradient centrifugation were stained with monoclonal phycoerythrin-labeled anti-CD19 antibodies (BD Pharmingen, San Jose, Calif), permeabilized (Fix and Perm Solution; Caltag Laboratories, Burlingame, Calif), and stained with antivimentin fluorescein isothiocyanate-labeled monoclonal antibody RV202 (Santa Cruz Biotechnology, Santa Cruz, Calif). The vimentin content was assessed in CD19 + gated cells by flow cytometry (FACScan; BD Biosciences, San Jose, Calif). Mean fluorescence intensity (MFI) of vimentin was compensated for the isotype control MFI.
ASSESSMENT OF IGV H GENE MUTATIONAL STATUS
The IgV H gene mutation status was assessed as previously described. 13 Patients were classified as having unmutated status if there was 98% to 100% homology with the germline IgV H gene sequence and mutated status if there was less than 98% IgV H gene homology.
STATISTICAL ANALYSES
The differences between percentages of smudge cells on peripheral blood smears generated by using different methods and by independent observers were compared using the tables for calculating the least significant differences for leukocyte differential counts with 200 cells and a 2-sided level of significance of 0.05 as developed by Rumke et al. 14 The nonparametric Spearman correlation test was used to assess correlations among continuous variables. The TTT was estimated using the Kaplan-Meier method, and differences between groups were assessed using the log-rank test. 15 Univariate and multivariate analyses were performed using the Cox proportional hazard regression model. 16 To discriminate between those who had a short TTT and those who had a longer TTT, a categorical variable for the percentage of smudge cells was defined using a minimum P value approach to identify the optimal cutpoint.
RESULTS
The clinical characteristics of the 75 eligible patients with blood smears are given in P=.002). The median survival for the entire cohort was not reached; the predicted 10-year overall survival rate was 77.2% (95% CI, 64%-93%).
PERIPHERAL BLOOD SMEAR
The median time from the date of diagnosis to the first available smear was 22 months (range, 0-162 months), and 39 patients (52%) had smears available for review within 24 months of diagnosis. In 15 patients, blood smear slides obtained at diagnosis were compared with slides made at later time points after diagnosis (median time between slides, 48 months; range, 9-72 months). The percentage of smudge cells had not changed significantly over time (P=.61).
The median ALC at the time the peripheral blood smear was made was 16.8 × Concordance was found between slides prepared using the Miniprep device and the Autoprep device in 29 (97%) of 30 readouts (Table 2) . 14 In contrast, slides prepared by the manual wedge method were concordant in 17 (57%) of 30 readouts. A 93% (28/30 readouts) concordance rate was (Figure 2, middle) . The difference between the groups remained statistically significant for a subset of patients with Rai stage 0 disease only ( Figure  2, bottom) . The estimated percentage of all patients with less than 30% smudge cells who required treatment within 10 years of diagnosis was 77% compared with 37% of patients with 30% or more smudge cells (P=.001). In a multivariate Cox model adjusted for Rai stage, the percentage of smudge cells (<30% vs ≥30%) and IgV H gene mutation status remained significant prognostic factors (Table 3) .
DISCUSSION
In 1896, Gumprecht 17 described the presence of smudge cells (also known as shadows of Gumprecht or basket cells) FIGURE 2. Kaplan-Meier plots show time from diagnosis to initial treatment (TTT) for all 75 patients (top) and for patients with 30% or more smudge cells vs those with less than 30% smudge cells for all patients (middle) (log rank P=.001) and patients with Rai stage 0 disease only (bottom) (log rank P=.001). The median TTT for the entire cohort was 95.3 months. Patients with less than 30% smudge cells on routine blood smears had a median TTT of 72.7 months, whereas the median TTT for patients with 30% or more smudge cells was not reached (P=.001). For patients with Rai stage 0 disease, median TTT was 76.3 months for patients with less than 30% smudge cells, and the median TTT was not reached for patients with 30% or more smudge cells (P=.01).
on the blood smears of patients with "lymphocytic leukemia." The formation of smudge cells was initially considered an unimportant artifact of slide preparation, reflecting the "fragility" of CLL cells. 18 In 1959 Heinivaara 8 made 2 intriguing observations: first, that the percentage of smudge cells was not dependent simply on the degree of lymphocy- tosis or the slide stain method, and second, that "smudging" appeared to be patient specific. In 1993, Binet et al 19 described a correlation between the presence of dense chromatin and the number of smudge cells and postulated that smudge cells are from lymphocytes on the "verge of apoptosis."
We recently reported that a high expression of the cytoskeleton protein vimentin is associated with the presence of an unmutated IgV H gene and shortened TTT. 9 Because vimentin is critical for lymphocyte rigidity, low vimentin expression could render cells more "fragile" and susceptible to smudging when making peripheral blood smears. We have now shown that low vimentin expression correlates with a high percentage of smudge cells on the peripheral blood smear. In addition to its mechanical role, vimentin is involved in signal transduction and cell activation of normal and malignant cells. [20] [21] [22] Vimentin expression is associated with adverse prognosis in patients with solid tumors. [22] [23] [24] In the current study, we demonstrate that the percentage of smudge cells on a peripheral blood smear is lower in patients with unmutated IgV H genes and that the percentage of smudge cells as a continuous variable correlates with both TTT and overall survival. The cutoff of 30% smudge cells was identified on the basis of the minimal P value approach and stratified patients into 2 groups with significantly different TTT. Importantly, similar to other investigators, we found no correlation between ALC and the percentage of smudge cells, and the percentage of smudge cells in patients did not change significantly over time. These findings indicate that the percentage of smudge cells is not simply a surrogate marker of disease burden but reflects differences in the biologic characteristics of the leukemic cells.
Simple semiautomatic devices (Miniprep and Autoprep) and the manual wedge method are routinely used to prepare slides in hematopathology laboratories. In our study, generation of blood smears with semiautomatic devices yielded consistent smudge cell percentages; however, significant differences in intraobserver and interobserver counts were seen when the manual wedge method was used. This finding is consistent with previous findings, likely reflecting the nonuniform spread with the manual method. The reproducibility of a white cell differential count can be improved by counting more cells per slide. 25 Whether counting more than 200 cells to estimate the percentage of smudge cells would improve reproducibility of all the methods used remains to be established. Currently, we recommend using slides prepared by semiautomatic methods and a minimum of a 200-cell count for future studies.
CONCLUSION
Our finding that the high percentage of smudge cells on a peripheral blood smear is associated with mutated IgV H gene status, a longer TTT, and better overall survival in patients with early-stage CLL could provide a simple and inexpensive prognostic test available to nearly all patients worldwide with a diagnosis of CLL.
